Malta - Inggris - Malta Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - gemcitabine hydrochloride - concentrate for solution for infusion - gemcitabine hydrochloride 40 mg - antineoplastic agents

Malta - Inggris - Malta Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - gemcitabine hydrochloride - concentrate for solution for infusion - gemcitabine hydrochloride 40 mg - antineoplastic agents

Malta - Inggris - Malta Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - gemcitabine hydrochloride - concentrate for solution for infusion - gemcitabine hydrochloride 40 mg - antineoplastic agents

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gemcitabine hydrochloride, quantity: 2278 mg (equivalent: gemcitabine, qty 2000 mg) - injection, concentrated - excipient ingredients: dilute hydrochloric acid; water for injections - treatment of patients with locally advanced or metastatic non-small cell lung cancer. ? treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ? treatment of patients with 5fu refractory pancreatic cancer. ? treatment of patients with bladder cancer, alone or in combination with cisplatin. ? treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ? treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed > six months following platinum based therapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gemcitabine hydrochloride, quantity: 227.8 mg (equivalent: gemcitabine, qty 200 mg) - injection, concentrated - excipient ingredients: dilute hydrochloric acid; water for injections - treatment of patients with locally advanced or metastatic non-small cell lung cancer. ? treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ? treatment of patients with 5fu refractory pancreatic cancer. ? treatment of patients with bladder cancer, alone or in combination with cisplatin. ? treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ? treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed > six months following platinum based therapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gemcitabine hydrochloride, quantity: 1139 mg (equivalent: gemcitabine, qty 1000 mg) - injection, concentrated - excipient ingredients: water for injections; dilute hydrochloric acid - ? treatment of patients with locally advanced or metastatic non-small cell lung cancer. ? treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ? treatment of patients with 5fu refractory pancreatic cancer. ? treatment of patients with bladder cancer, alone or in combination with cisplatin. ? treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ? treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed > six months following platinum based therapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - gemcitabine hydrochloride, quantity: 228 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: mannitol; sodium acetate trihydrate; sodium hydroxide; hydrochloric acid - treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. treatment of patients with 5-fu refractory pancreatic cancer. treatment of patients with bladder cancer, alone or in combination with cisplatin. treatment, in combination with paclitaxel, of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed > six months following platinum based therapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gemcitabine hydrochloride, quantity: 569.5 mg (equivalent: gemcitabine, qty 500 mg) - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; sodium acetate trihydrate - gemcitabine sandoz is indicated for treatment of patients with:. - locally advanced or metastatic non-small cell lung cancer (nsclc). - locally advanced or metastatic adenocarcinoma of the pancreas . - fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.. - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gemcitabine hydrochloride, quantity: 1139 mg (equivalent: gemcitabine, qty 1000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections; sodium acetate trihydrate - gemcitabine sandoz is indicated for treatment of patients with:. - locally advanced or metastatic non-small cell lung cancer (nsclc). - locally advanced or metastatic adenocarcinoma of the pancreas . - fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.. - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gemcitabine hydrochloride, quantity: 227.8 mg (equivalent: gemcitabine, qty 200 mg) - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; sodium acetate trihydrate - gemcitabine sandoz is indicated for treatment of patients with:. - locally advanced or metastatic non-small cell lung cancer (nsclc). - locally advanced or metastatic adenocarcinoma of the pancreas . - fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.. - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.